Hikma reported a robust performance in Q2, driven by a drug shortage in the US, excellent demand pick-up in MENA, resilient generics and the introduction of new products. We have upgraded our target price based on improved management quality, reflecting in the current execution and the company’s agility in quickly picking up any demand surge or supply woes at rivals. However, the deteriorating operating environment for generics and a limited R&D pipeline remain a major concern, in o
01 Oct 2018
Launches, shortage and cost management forge a surprise
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Launches, shortage and cost management forge a surprise
Hikma Pharmaceuticals Plc (HIK:LON) | 1,810 -108.6 (-0.3%) | Mkt Cap: 4,017m
- Published:
01 Oct 2018 -
Author:
Kamla Singh -
Pages:
3
Hikma reported a robust performance in Q2, driven by a drug shortage in the US, excellent demand pick-up in MENA, resilient generics and the introduction of new products. We have upgraded our target price based on improved management quality, reflecting in the current execution and the company’s agility in quickly picking up any demand surge or supply woes at rivals. However, the deteriorating operating environment for generics and a limited R&D pipeline remain a major concern, in o